Twist Bioscience Corporation (TWST) Stock: Price, Forecast & Analyst Target
Twist Bioscience Corporation (TWST) — MoonshotScore 36/100 (Weak band), calculated Oct 5, 2026. Price $205.00 (+8.66%), as of the Oct 5, 2026 trading session; market cap $12.8B. Expected results Nov 13, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 76.72× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 13, 2026
Twist Bioscience Corporation · TWST · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Twist Bioscience manufactures synthetic DNA on a silicon-based platform and sells sequencing tools, synthetic genes, oligo pools, libraries and antibody-discovery capabilities to research and biopharma customers. Its case depends on whether sustained demand and manufacturing scale can turn expanding gross profit into durable cash generation before the remaining liquidity cushion materially erodes.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Twist Bioscience (TWST)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth — and it’s docked well below the pillars; verify the gap before trusting the setup. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $118M (Q3 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 28.47 · Piotroski F 2
Helping: durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak |
The score was 36 in the stored Oct 4, 2026 snapshot and remains 36 in the current publication computed Oct 5, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $205.00 | |
| Change on the day | +8.66% | |
| 52-week range | $23.30 – $200.31 | |
| Market capitalisation | $12.8B | |
| Shares traded on the day | 3.20M | |
| Beta (volatility vs the S&P 500) | 2.22 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Our gross margin for the third quarter was 52.8%, up sequentially and driven by strong revenue growth even as we continue to make deliberate investments in new product offerings and manufacturing capacity that we expect to result in future margin gains as we accelerate growth and implement continuous process improvements.
Adam Laponis · Statement from
For Q4 of fiscal 2026, we expect total revenue of $123 million to $124 million, growth of approximately 25% year-over-year at the midpoint.
Adam Laponis · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Twist Bioscience (TWST): Split View
44/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the TWST film — every key number, told as a short cinematic story
~2 min · open the film
What is Twist Bioscience (TWST), and what does it report?
Short answer · as of
Twist is better understood as a supplier to biotechnology research than as a conventional drug developer.
Research dated 2026-09-13.
Twist is better understood as a supplier to biotechnology research than as a conventional drug developer. Customers buy manufactured DNA and workflow tools; revenue therefore reflects demand for sequencing preparation, genes, oligo pools, libraries and discovery services rather than clinical progress for a proprietary medicine.
Sequencing tools form the largest reported business, with synthetic genes providing another substantial revenue stream. Antibody discovery and library products broaden Twist’s exposure to pharmaceutical research, but they remain parts of a diversified synthetic-biology catalog.
What do the latest results show for Twist Bioscience (TWST)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $118M.
Research dated 2026-09-13.
Revenue and gross profit have risen throughout the reported quarterly series. The latest period extended that progression and narrowed the operating loss from the preceding period, yet the company remained unprofitable and earnings fell short of expectations even as revenue exceeded them.
Management attributes the latest gross-margin improvement to revenue growth while continuing to invest in new offerings and manufacturing capacity. That explanation is prospective as well as descriptive: the spending is intended to support further margin gains, so rising sales without improving operating economics would weaken the scaling argument.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $118.38M Jun 30, 2026
- Latest quarter · R&D
- $18.02M Jun 30, 2026
- Latest quarter · SG&A
- $80.71M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$36.28M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $118.38M | $18.02M | $80.71M | −$36.28M |
| Mar 31, 2026 | $110.72M | $19.70M | $76.08M | −$38.66M |
| Dec 31, 2025 | $103.70M | $17.13M | $69.74M | −$32.90M |
| Sep 30, 2025 | $99.01M | $17.01M | $63.76M | −$29.93M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $118.40M Aug 3, 2026
- Latest report · revenue estimate
- $114.55M Aug 3, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 3, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 3, 2026 | $118.40M | $114.55M | −$0.5600 | −$0.5062 |
| May 4, 2026 | $110.72M | $107.64M | −$0.7100 | −$0.4900 |
| Feb 2, 2026 | $103.70M | $101.88M | −$0.5000 | −$0.4800 |
| Nov 14, 2025 | $99.01M | $97.40M | −$0.4500 | −$0.5000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $118M | -$35M | -$0.56 (diluted) |
| Q2 FY2026 | $111M | -$44M | -$0.71 (diluted) |
| Q1 FY2026 | $104M | -$31M | -$0.50 (diluted) |
| Q4 FY2025 | $99M | -$27M | -$0.45 (diluted) |
What are the financial strengths and risks for Twist Bioscience (TWST)?
Short answer
Cash and short-term investments were $166.84M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $1.12M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments exceed total debt, and longer-term investments add to the available financial resources. Liquidity ratios and the distress screen do not indicate an immediate balance-sheet constraint, while the latest quarter produced positive operating cash flow.
The longer record is less comfortable. Cash has declined materially across the reported window, capital spending continues, free cash flow remains negative and the estimated runway is finite. A demanding sales valuation leaves limited protection if revenue growth slows before operating expenses and manufacturing investment yield sustained cash generation.
Data-derived red flags
- Negative return on equity (-29.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $1.12M Jun 30, 2026
- Previous quarter · operating cash flow
- −$17.56M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $1.12M | −$9.66M |
| Mar 31, 2026 | −$17.56M | −$7.99M |
| Dec 31, 2025 | −$24.81M | −$9.97M |
| Sep 30, 2025 | −$11.81M | −$12.43M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Twist Bioscience (TWST)?
Short answer · as of
The next earnings report is expected on Nov 13, 2026.
Research dated 2026-09-13.
The upcoming report needs to preserve the sequential revenue pattern and land near management’s stated outlook. More important, gross-margin progress must begin carrying through to a smaller operating loss rather than being absorbed by selling, administrative and development spending.
Positive operating cash flow in the latest period is useful only if it becomes repeatable after capital expenditure. Watch whether cash and short-term investments stabilize, whether gross profit continues to outpace operating costs, and whether revenue beats stop arriving alongside earnings misses.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Our gross margin for the third quarter was 52.8%, up sequentially and driven by strong revenue growth even as we continue to make deliberate investments in new product offerings and manufacturing capacity that we expect to result in future margin gains as we accelerate growth and implement continuous process improvements.
Adam Laponis ·
For Q4 of fiscal 2026, we expect total revenue of $123 million to $124 million, growth of approximately 25% year-over-year at the midpoint.
Adam Laponis ·
We believe we have a strong growth trajectory to more than double revenue from organic growth in 2031.
Emily Leproust ·
We expect gross margin above 52% for fiscal 2026 with a goal of margins of more than 60% as the business matures.
Emily Leproust ·
How does Twist Bioscience compare with its peers?
Short answer
Twist Bioscience's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Drug developers usually concentrate risk in clinical assets; Twist sells the DNA inputs and workflow products used across many research programs. Its economics are consequently tied more directly to customer ordering, product mix, manufacturing efficiency and sequencing activity than to approval of a medicine owned by Twist.
The silicon synthesis platform also supports a broader catalog than sequencing tools alone. Synthetic genes, oligo pools, DNA libraries and antibody discovery let Twist serve research demand through distinct products, although sequencing tools remain the largest reported source of revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.85 Oct 5, 2026 | $14.8B | 98 5-pillar Oct 5, 2026 | |
| $334.85 Oct 5, 2026 | $9.50B | 98 5-pillar Oct 5, 2026 | |
| $114.13 Oct 5, 2026 | $23.1B | 98 5-pillar Oct 5, 2026 | |
| $108.31 Oct 5, 2026 | $12.9B | 97 5-pillar Oct 5, 2026 | |
| $536.40 Oct 5, 2026 | $23.0B | 97 5-pillar Oct 5, 2026 | |
| $72.58 Oct 5, 2026 | $11.4B | 93 5-pillar Oct 5, 2026 | |
| $144.21 Oct 5, 2026 | $14.5B | 92 5-pillar Oct 5, 2026 | |
| $122.03 Oct 5, 2026 | $13.1B | 91 5-pillar Oct 5, 2026 | |
| $30.39 Oct 5, 2026 | $8.54B | 89 5-pillar Oct 5, 2026 | |
| $228.03 Oct 5, 2026 | $14.2B | 88 5-pillar Oct 5, 2026 | |
| $140.63 Oct 5, 2026 | $9.08B | 75 5-pillar Oct 5, 2026 | |
| $56.66 Oct 5, 2026 | $25.1B | 73 5-pillar Oct 5, 2026 | |
| Twist Bioscience (TWST) — this page | $205.00 | $12.8B | 36 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $89.00 – $212.00
- Consensus target
- $131.33
- Median target
- $115.00
Consensus record · Captured .
Measured against a quoted price of $205.00 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 24, 2026
- Transactions
- 100
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 82
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 348 Period end Jun 30, 2026
- Previous quarter · holders
- 287 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 5,833,891 |
| Artisan Partners Limited Partnership | 4,802,017 |
| Fmr LLC | 4,703,044 |
| Ark Investment Management LLC | 4,549,803 |
| Price T Rowe Associates INC /Md/ | 3,634,652 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Twist Bioscience (TWST)?
TWST Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do sequencing tools matter so much to Twist Bioscience?
Sequencing tools are Twist’s largest reported revenue category, making customer demand for sample-preparation and sequencing workflows especially important to companywide growth. The synthetic-gene business provides meaningful diversification, but it does not displace that concentration.
How does Twist Bioscience use silicon to manufacture DNA?
Twist writes synthetic DNA directly onto silicon chips, then sells products derived from that platform. The commercial value lies in supplying genes, oligo pools, sequencing tools and libraries across research workflows rather than pursuing only a proprietary drug pipeline.
Is antibody discovery the main business at Twist Bioscience?
Antibody discovery gives Twist exposure to pharmaceutical research and therapeutic-antibody collaborations, but it is much smaller than sequencing tools and synthetic genes in the reported revenue mix. It complements the core synthetic-DNA platform rather than defining the company by itself.
Can Twist Bioscience keep funding manufacturing expansion while losses continue?
The balance sheet provides room to keep investing, and operating cash flow recently turned positive. Continued cash decline, recurring capital spending and persistent operating losses mean that room depends on revenue growth and margin gains translating into repeatable cash generation.
What is the TWST stock price today?
The last price recorded on this page for Twist Bioscience Corporation (TWST) is $205.00, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TWST price target?
The analyst consensus price target for Twist Bioscience Corporation (TWST) is $131.33 (range $89.00 to $212.00, median $115.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Adam Laponis (Aug 3, 2026): Our gross margin for the third quarter was 52.8%, up sequentially and driven by strong revenue growth even as we continue to make deliberate investments in new product offerings and manufacturing capacity that we expect to result in future margin gains as we accelerate growth and implement continuous process improvements. Adam Laponis (Aug 3, 2026): For Q4 of fiscal 2026, we expect total revenue of $123 million to $124 million, growth of approximately 25% year-over-year at the midpoint. Emily Leproust (Aug 3, 2026): We believe we have a strong growth trajectory to more than double revenue from organic growth in 2031. Emily Leproust (Aug 3, 2026): We expect gross margin above 52% for fiscal 2026 with a goal of margins of more than 60% as the business matures. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | South SAN Francisco, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "681 Gateway Boulevard, South San Francisco, CA, 94080, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 13, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $205.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:53.233Z. | |
px.change | Change on the day | +8.66% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.8B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:00.000Z. Captured from FMP at 2026-10-05T21:44:52.202Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$16.33 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $118M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 3.20M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 2.22 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Emily Marine Leproust | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 979 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $132.33M, net result −$152.10M; FY2022 revenue $203.57M, net result −$217.86M; FY2023 revenue $245.11M, net result −$204.62M; FY2024 revenue $312.97M, net result −$208.73M; FY2025 revenue $376.57M, net result −$77.67M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Ngs Tools $208.10M · Oligo Pools $20.23M · Synthetic Genes $113.60M · Antibody Discovery $23.45M · Dna And Biopharma Libraries $11.18M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 52.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $118.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $18.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $80.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$36.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $110.72M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $19.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $76.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$38.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $103.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $17.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $69.74M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$32.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $99.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $17.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $63.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$29.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-03.revenue_actual | Revenue · reported — report date 2026-08-03 | $118.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.revenue_estimated | Revenue · estimate — report date 2026-08-03 | $114.55M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_actual | EPS · reported — report date 2026-08-03 | −$0.5600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_estimated | EPS · estimate — report date 2026-08-03 | −$0.5062 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_actual | Revenue · reported — report date 2026-05-04 | $110.72M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_estimated | Revenue · estimate — report date 2026-05-04 | $107.64M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_actual | EPS · reported — report date 2026-05-04 | −$0.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_estimated | EPS · estimate — report date 2026-05-04 | −$0.4900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.revenue_actual | Revenue · reported — report date 2026-02-02 | $103.70M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.revenue_estimated | Revenue · estimate — report date 2026-02-02 | $101.88M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.eps_actual | EPS · reported — report date 2026-02-02 | −$0.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.eps_estimated | EPS · estimate — report date 2026-02-02 | −$0.4800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.revenue_actual | Revenue · reported — report date 2025-11-14 | $99.01M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.revenue_estimated | Revenue · estimate — report date 2025-11-14 | $97.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_actual | EPS · reported — report date 2025-11-14 | −$0.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_estimated | EPS · estimate — report date 2025-11-14 | −$0.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $166.84M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $1.12M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $70.22M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $93.59M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 26.41× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $1.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$17.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$9.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$7.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$24.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$9.97M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$11.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$12.43M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $89.00 – $212.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $131.33 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $115.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 100 transactions · 0 purchases, 82 sales, 18 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 24, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 348 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 287 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 5,833,891 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Artisan Partners Limited Partnership — shares in provider snapshot | 4,802,017 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Fmr LLC — shares in provider snapshot | 4,703,044 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Ark Investment Management LLC — shares in provider snapshot | 4,549,803 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 3,634,652 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-23 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 28.47 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
px.range52 | 52-week range | $23.30 – $200.31 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -29.9% · ROA -20.3% · current ratio 2.67 · earnings yield -1.2% · free-cash-flow yield -0.8% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 76.72× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $166.84M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-03.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($118.40M) with the recorded estimate ($114.55M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-03.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.5600) with the recorded estimate (−$0.5062) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 36 of 100 · Weak · pillars 51 / 56 / 43 / 77 / 100 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 36 (stored snapshot Oct 4, 2026) → 36 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-03.revenue_actual,earn.history.depth.2026-08-03.revenue_estimated,earn.history.depth.2026-08-03.revenue_actual.comparison,earn.history.depth.2026-08-03.eps_actual.comparison,earn.history.depth.2026-08-03.eps_actual,earn.history.depth.2026-08-03.eps_estimated,earn.history.depth.2026-05-04.revenue_actual,earn.history.depth.2026-05-04.revenue_estimated,earn.history.depth.2026-05-04.eps_actual,earn.history.depth.2026-05-04.eps_estimated,earn.history.depth.2026-02-02.revenue_actual,earn.history.depth.2026-02-02.revenue_estimated,earn.history.depth.2026-02-02.eps_actual,earn.history.depth.2026-02-02.eps_estimated,earn.history.depth.2025-11-14.revenue_actual,earn.history.depth.2025-11-14.revenue_estimated,earn.history.depth.2025-11-14.eps_actual,earn.history.depth.2025-11-14.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Twist Bioscience Corp Our market-data provider lists the name as "Twist Bioscience Corporation"; the filer's own record is used here. | 2025-11-17 | OFFICIAL | SEC EDGAR — 10-K filed 2025-11-17 |
| Business description | Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Ngs Tools: $208.10M; Oligo Pools: $20.23M; Synthetic Genes: $113.60M; Antibody Discovery: $23.45M; Dna And Biopharma Libraries: $11.18M | 2025-09-30 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-09-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-03 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-03 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $93.59M; Liquidity basis: cash and short-term investments; Total liabilities: $226.70M; Cash and short-term investments: $166.84M; Cash and investments: $237.10M; Long-term investments: $70.22M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $237.10M; Cash and short-term investments: $166.80M; Long-term investments: $70.20M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $166.80M; Decline: $109.60M; Opening balance: $276.40M; Average change per period: $15.70M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash runway cross-check (ours) | Years: 2.1; Method: cash and short-term investments of $166.8M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($80.9M per year); Reaches: 2028-07; Cash basis: cash and short-term investments; Cash: $166.80M; Annualized cash use: $80.90M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Trailing twelve-month ratio set | Quick ratio: 2.38; Current ratio: 2.67; Debt to equity: 0.21; Net margin: -31.7%; Gross margin: 52%; Operating margin: -31.9%; Return on assets: -20.3%; Return on equity: -29.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 18.34; Piotroski F-score: 2 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $73.20M; Total debt: $93.60M; Cash and investments: $166.80M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-13; EPS estimate: -$0.44 per share; Revenue estimate: $123.51M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold TWST
Funds in our ETF coverage that list TWST among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 3.71% |